IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ROTHMAN et al.

Group Art Unit: Unassigned

Application No. Unassigned

Examiner: Unassigned

Filed: December 1, 2003

For: BIOLOGICAL FLUID TREATMENT

SYSTEM

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as

In re Appln. of ROTHMAN et al. Application No. Unassigned

	of a fir	th in 37 CFR 1.491 of an international application; (c) before the mailing date st Office Action on the merits; or (d) before the mailing of a first Office Action he filing of a request for continued examination under 37 CFR 1.114.
	37 CF	(a), (b), (c) or (d) above, but before the mailing date of a final action under R 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that ise closes prosecution in the application, and includes <i>one</i> of:
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	under and or 37 CFI	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, or before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as the in 37 CFR 1.17(p) (see "Fees" below).
	payme contain 37 CFI \$180 a NOTE: May 29,	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before int of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of s set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after 2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.
Copie	s of the	References
\boxtimes	A15 th in the CFR 1 abstrace patent found	of references listed on the enclosed Form 1449 (other than A1-A11 and A13- at are discussed below) are enclosed herewith. Attached to each reference not English language is a concise explanation of the relevance pursuant to 37 .98(a)(3). An English-language equivalent/patent, or an English-language et, or an English-language version of the search report or action by a foreign office in a counterpart foreign application indicating the degree of relevance by the foreign office is being submitted in lieu of a concise explanation of the ace pursuant to 37 CFR 1.98(a)(3).
	A copy	of the foreign search report is enclosed herewith.
	previous of the reference copies reference	eferences A1-A11 and A13-A15 listed on the enclosed Form 1449 were usly identified in the parent application(s) of the present application, and copies references were furnished at that time. Accordingly, additional copies of the ices are not submitted herewith, so as not to burden the file with duplicate of references. The Examiner is respectfully requested to carefully review the ices in accordance with the requirements set out in the Manual of Patent ning Procedure. In accordance with 37 CFR 1.98(d), the details of the parent

In re Appln. of ROTHMAN et al. Application No. Unassigned

application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPL	ICATIONS	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1. 09/600,752	July 21, 2000	X			
2. 10/287,497	November 5, 2002		X		
3.					

State	ment under 37 CFR 1.97(e)
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
State	ment under 37 CFR 1.704(d)
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
Fees	
	No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.
Meth	od of Payment of Fees
	Attached is a check in the amount of \$. Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose)

In re Appln. of ROTHMAN et al. Application No. Unassigned

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 12-1216.

Respectfully submitted,

eremy M. Jay, Reg. No. 83,587

DEYDIC VOIT & MAYER 700 Thirteenth Street, N.W., Suite 300

Washington, DC 20005-3960

(202) 737-6770 (telephone) (202) 737-6776 (facsimile)

Date: 5 Dec. 2003

IDS (Revised 8/26/03)

Please type a plus sign (+) inside this box ->	+
--	---

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(Use as many sheet	s as nec	cessary)
Sheet	1	of	

Complete if Known					
Application Number					
Filing Date	December 1, 2003				
First Named Inventor	Isaac Rothman				
Group Art Unit					
Examiner Name					
Attorney Docket Number	440833/PALL				

			U	S. PATENT DOCUMENTS		
U.S. Patent Document					Data of	Fillian Data II
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	A 1	4,235,233		Mouwen	11/1980	
	A 2	4,466,888		Verkaart, Wesley H.	8/1984	
	Α3	4,734,269		Clarke et al.	3/1988	
	A 4	4,880,548		Pall et al.	11/1989	
	A 5	4,978,578		Kanno et al.	12/1990	
	Α6	5,100,624		Pall et al.	3/1992	
	Α7	5,217,627		Pall et al.	6/1993	
	A 8	5,421,824		Clement et al.	6/1995	
	Α9	5,695,489		Japuntich	12/1997	
	A10	5,928,516		Hopkins et al.	7/1999	
	A 1 1	6,099,734		Boggs et al.	8/2000	
	A12	6,497,823		Rothman et al.	12/2002	
				-		

	_			FOREIG	N PATENT DOCUMENTS			
		F	oreign Patent Documen	t			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	A13	EP	0 230 247 A		Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	7/1987		
	A14	PCT	WO 91/04088		Pall Corporation	4/1991		
	A 1 5	PCT	WO 93/04763 A		Pall Corporation	3/1993		
					-			

OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Translation				
Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**			
	-						

Evaminar Signatura	•	Data Canaidarad	
Examiner Signature		Date Considered	
_			

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).